Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Bullish Despite Biosimilars Battering

Pharma Sales Down By 7% in Q4

Executive Summary

Its older oncology products are sinking but the Swiss major is confident about coming through COVID-19 in a strong position.

You may also be interested in...



Roche Takes Advantage Of COVID-19 Testing Rush

Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.

Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19

After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.

Bayer Ponders Road Less Traveled And Trip Savings In Pandemic

Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."

Topics

Related Companies

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel